Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Aaronson

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Psychiatry|March 15, 2019
The Evolving Concept of a Therapeutic CommunityScott T Aaronson, Maria Mouratidis
The Journal of Clinical Psychiatry|May 30, 2024
The Long Road Toward Equitable MDMA Treatment in the United StatesZofia Kozak, Scott T Aaronson
Med (New York, N.Y.)|February 15, 2024
New evidence for flexible psilocybin dosing in patients with treatment-resistant depressionScott T Aaronson, Zofia Kozak
Current Psychiatry Reports|September 21, 2022
The Emerging Field of Psychedelic PsychotherapyGregory S Barber, Scott T Aaronson
The Psychiatric Clinics of North America|August 13, 2018
NeuromodulationScott T Aaronson, Noah S Philip
The Psychiatric Clinics of North America|August 13, 2018
Vagus Nerve Stimulation: Changing the Paradigm for Chronic Severe Depression?Scott T Aaronson, Charles R Conway
The Australian and New Zealand Journal of Psychiatry|November 1, 2018
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusiveAugustus John Rush, Scott T Aaronson, Koen Demyttenaere
Expert Opinion on Investigational Drugs|October 23, 2023
Assessing potential of psilocybin for depressive disordersZofia Kozak, Matthew W Johnson, Scott T Aaronson
Brain and Behavior|November 10, 2020
A retrospective analysis of bipolar depression treated with transcranial magnetic stimulationEric L Goldwaser, Kathy Daddario, Scott T Aaronson
JAMA Psychiatry|April 10, 2024
Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-ReplyScott T Aaronson, Andrew van der Vaart, Harold A Sackeim
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Psychiatry|March 15, 2019
The Evolving Concept of a Therapeutic CommunityScott T Aaronson, Maria Mouratidis
The Journal of Clinical Psychiatry|May 30, 2024
The Long Road Toward Equitable MDMA Treatment in the United StatesZofia Kozak, Scott T Aaronson
Med (New York, N.Y.)|February 15, 2024
New evidence for flexible psilocybin dosing in patients with treatment-resistant depressionScott T Aaronson, Zofia Kozak
Current Psychiatry Reports|September 21, 2022
The Emerging Field of Psychedelic PsychotherapyGregory S Barber, Scott T Aaronson
The Psychiatric Clinics of North America|August 13, 2018
NeuromodulationScott T Aaronson, Noah S Philip
The Psychiatric Clinics of North America|August 13, 2018
Vagus Nerve Stimulation: Changing the Paradigm for Chronic Severe Depression?Scott T Aaronson, Charles R Conway
The Australian and New Zealand Journal of Psychiatry|November 1, 2018
Difficult-to-treat depression: A clinical and research roadmap for when remission is elusiveAugustus John Rush, Scott T Aaronson, Koen Demyttenaere
Expert Opinion on Investigational Drugs|October 23, 2023
Assessing potential of psilocybin for depressive disordersZofia Kozak, Matthew W Johnson, Scott T Aaronson
Brain and Behavior|November 10, 2020
A retrospective analysis of bipolar depression treated with transcranial magnetic stimulationEric L Goldwaser, Kathy Daddario, Scott T Aaronson
JAMA Psychiatry|April 10, 2024
Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-ReplyScott T Aaronson, Andrew van der Vaart, Harold A Sackeim
Pageof 8